Benign Prostatic Hyperplasia & Prostate Cancer: a review on the treatment strategies

Abstract

About 15% of prostate cancer diagnoses are due to high-risk conditions and the best way to treat this patient are always changing. To allow the accurate identification of high-risk illnesses and the creation of more effective treatment pattern, a new classification method is necessary. The Food & Drug Administration has authorized the newest innovative prostate-specific membrane antigen Pluvicto as a prostate cancer therapy. A percent of old citizens that do meet the criteria for the prostate-specific membrane antigen and have prostate cancer which is known as metastatic castration-resistant prostate cancer are now advised to use Pluvicto. Biomarkers are substances that are used to reveal either regular or irregular bodily activities for determining prostate cancer by prostate-specific antigen, 4 Kallikreins score, and prostate cancer gene 3 level. Moreover, this project highlights the advanced treatment strategies along with their mechanisms to cure prostate cancer and benign prostatic hyperplasia.